Cathie Wood’s ARK sells stock in Personalised Inc, buys Compass Pathways
On Monday, October 12th, 2026, Cathie Wood's ARK ETF disclosed a series of notable stock transactions. The most significant was the divestment of 730,303 shares from Personalised Inc. (PSNL) through the ARKG ETF, valued at $11,684,848. This sale aligns with ARK's recent pattern of decreasing its holdings in Personalised Inc. Notably, ARK increased its stake in Compass Pathways PLC (CMPS) by purchasing 284,019 shares via the ARKG ETF, amounting to $3,408,228.
This investment highlights ARK's expanding interest in mental health treatment. ARK also sold 229,471 shares of DraftKings Inc. (DKNG) across the ARKW and ARKF ETFs, totaling $4,493,042, as part of a continued strategy of reducing exposure to DraftKings. Conversely, ARK bolstered its position in Alamar Biosciences Inc. (ALMR) by acquiring 101,154 shares through the ARKG ETF, valued at $2,556,161, following a previous purchase of 31,068 shares the previous day.
ARK's interest in gene-editing technologies was underscored by the acquisition of 43,887 shares of CRISPR Therapeutics AG (CRSP) via the ARKG ETF, worth $2,343,126. Additional modest purchases included 136,894 shares of Freenome, Inc. (FRNM) and 12,720 shares of Guardant Health, Inc. (GH), valued at $2,160,187 and $2,130,218, respectively.
Conversely, ARK divested 4,520 shares of Meta Platforms, Inc. (META) through the ARKK ETF, valued at $3,248,388. These transactions reflect Cathie Wood's strategic approach, balancing divestments in certain sectors while increasing exposure to innovative biotech firms and emerging technologies.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
